Abstracts tagged "malignancy and systemic lupus erythematosus"

Abstract Number: 2475 • 2012 ACR/ARHP Annual Meeting
Cancer in Pediatric-Onset Systemic Lupus: What Is the Role of Disease Duration and Other Factors on Risk?
Sasha Bernatsky¹, Ann E. Clarke¹, Jeremy Labrecque², Emily von Scheven³, Laura E. Schanberg⁴, Earl D. Silverman⁵, Hermine Brunner⁶, Kathleen A. Haines⁷, Randy Q. Cron⁸, Kathleen M. O'Neil⁹, Kiem Oen¹⁰, Alan M. Rosenberg¹¹, Ciaran M. Duffy¹², Jennifer LF Lee¹³, Mruganka Kale¹³, Elizabeth M. Turnbull¹⁴ and Rosalind Ramsey-Goldman¹⁵, ¹Clinical Epidemiology, McGill University, Montreal, QC, Canada, ²Clinical Epidemiology, Research Institute of the McGill Univ. Health Ctre, Montreal, QC, Canada, ³Pediatric Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴Pediatrics, Duke University Medical Center, Durham, NC, ⁵PRSCG, Cincinnati, OH, ⁶Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Department of Pediatrics, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ⁸Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁹Division of Pediatric Rheum, Okla Univ Health Science Ctr, Oklahoma City, OK, ¹⁰Pediatrics, Children's Hospital of Winnipeg and University of Manitoba, Winnipeg, MB, Canada, ¹¹Department of Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ¹²Rheumatology, Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ¹³Clinical Epidemiology Rheum, RI McGill Univ Health Ctr, Montreal, QC, Canada, ¹⁴Research Institute of the McGill Univ. Health Ctre, Montreal, QC, Canada, ¹⁵Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Compared to adults with SLE, relatively little is known about cancer risk in pediatric-onset SLE. We assessed cancer incidence in a multi-centre pediatric-onset SLE…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].